

¹⁸F-FDG PET and Combined ¹⁸F-FDG–Contrast CT Parameters as Predictors of Tumor Control for Hepatocellular Carcinoma After Stereotactic Ablative Radiotherapy

Wen-Yen Huang^{*1,2}, Chia-Hung Kao^{*3,4}, Wen-Sheng Huang⁵, Chang-Ming Chen¹, Li-Ping Chang⁶, Meei-Shyuan Lee⁷, Hsing-Lung Chao¹, Chuang-Hsin Chiu^{8,9}, Cheng-Hsiang Lo¹, Yee-Min Jen¹

¹Department of Radiation Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan; ²Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan; ³Institute of Clinical Medicine Science and School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan; ⁴Department of Nuclear Medicine and PET Center, China Medical University Hospital, Taichung, Taiwan; ⁵Departments of Medical Research and Nuclear Medicine, Changhua Christian Hospital, Changhua, Taiwan; ⁶Department of Radiation Oncology, Cardinal Tien Hospital, Taipei, Taiwan; ⁷School of Public Health, National Defense Medical Center, Taipei, Taiwan; ⁸Department of Nuclear Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan; and ⁹Institute of Medical Science, National Defense Medical Center, Taipei, Taiwan

The application of stereotactic ablative radiotherapy (SABR) to hepatocellular carcinoma (HCC) is emerging. To identify pretreatment prognostic indicators is crucial for patient selection and optimal individual therapy. The aim of this study was to determine whether ¹⁸F-FDG PET and a combined ¹⁸F-FDG–contrast CT parameter could be useful tools to predict tumor control for patients with HCC treated by SABR. **Methods:** We retrospectively identified 31 patients (41 tumors) who underwent ¹⁸F-FDG PET before SABR between November 2007 and September 2011. ¹⁸F-FDG PET parameters were collected as prognostic indicators, including visual PET scale (+/–), maximal standardized uptake value (SUV) of the tumor (T_{SUVmax}), ratio of T_{SUVmax} to maximal normal-liver SUV, ratio of T_{SUVmax} to mean normal-liver SUV, and score combining tumor volume and T_{SUVmax} (CT/¹⁸F-FDG PET score). They underwent SABR with a median dose of 42 Gy (ranging from 30 to 50 Gy) in 4–5 fractions. ¹⁸F-FDG PET parameters and clinical factors were tested as predictors of tumor control and patient survival.

Results: The median follow-up time was 18 mo. Among the parameters examined, T_{SUVmax} and CT/¹⁸F-FDG PET score were significantly correlated with tumor control. T_{SUVmax} with a cutoff value of 3.2 was the most significant prognostic indicator. The 4-y control rate was 86.2% in tumors with a T_{SUVmax} of 3.2 or less but only 37.5% in those with a T_{SUVmax} of more than 3.2 (adjusted hazard ratio, 9.40; 95% confidence interval, 1.18–74.76; *P* = 0.034). CT/¹⁸F-FDG PET score (≤4 vs. >4) was also a significant predictor of tumor control after SABR. Tumors with a CT/¹⁸F-FDG PET score of more than 4 had a 5.23-fold risk of tumor failure. After adjustment for factors of sex, American Joint Committee on Cancer stage, Cancer of the Liver Italian Program score, and Child–Pugh classification, tumors with a score of more than 4 had a 4.96-fold risk of failure after SABR, compared with tumors with a score of 4 or less. For overall survival, none was statistically significant.

Conclusion: The use of ¹⁸F-FDG PET to predict tumor control is

feasible. T_{SUVmax} with a cutoff value of 3.2 is the best prognostic indicator. We suggest that ¹⁸F-FDG PET may be a reference for prognostic prediction, patient selection, and radiation dose adjustment for HCC patients treated with SABR.

Key Words: PET; hepatocellular carcinoma; stereotactic ablative radiotherapy; stereotactic body radiotherapy

J Nucl Med 2013; 54:1710–1716

DOI: 10.2967/jnumed.112.119370

Hepatocellular carcinoma (HCC) represents the main histologic type (70%–85%) of primary liver cancers, which are the fifth most frequently diagnosed cancer worldwide in men and the seventh in women. HCC is a fatal disease with an overall ratio of mortality to incidence of 0.93 (1,2). Surgical resection or transplantation is the treatment of choice (3). However, 80% of cases are unresectable at the time of diagnosis because of the underlying chronic liver disease and the presence of advanced disease. Alternatively, locoregional therapies may be used to palliate symptoms, to extend life, and to downstage the tumor to allow transplantation or resection. Of those, stereotactic ablative radiotherapy (SABR), also known as stereotactic body radiation therapy, is increasingly being used to treat unresectable HCC. It is an increasingly popular new radiation therapy technique with highly precise delivery of high-dose radiation to the target in a hypofractionated course under an image-guided setting. Publications on its safety and efficacy are emerging, and the results are promising (4–8). Nevertheless, a substantial fraction of patients experience tumor recurrence. How to identify useful pretreatment prognostic indicators and carefully select patients is therefore crucial for optimization of the application of SABR on HCC.

PET using ¹⁸F-FDG is a noninvasive functional technique with rapid expansion in clinical application over the past few years, especially in oncology. ¹⁸F-FDG PET is a useful tool for the staging and restaging of cancer, for detection of occult primary tumors, and for early prediction of treatment response

Received Jan. 11, 2013; revision accepted Apr. 30, 2013.

For correspondence or reprints contact: Yee-Min Jen, Department of Radiation Oncology, Tri-Service General Hospital, National Defense Medical Center, No. 325, Sec. 2, Cheng-Kong Rd., Nei-Hu 11490, Taipei, Taiwan.

E-mail: yeeminjen@yahoo.com.tw

*Contributed equally to this work.

Published online Aug. 22, 2013.

COPYRIGHT © 2013 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

TABLE 1
Patient Characteristics

Characteristic	Value
Number of patients	31
Number of lesions	41
Age (y)	
Mean \pm SD	63.8 \pm 10.5
Range	41–79
Sex	
Male	25
Female	6
ECOG score	
0	15
1	15
2	1
Viral hepatitis	
No	3
Hepatitis B virus	20
Hepatitis C virus	8
AJCC stage	
I	8
II	8
IIIA	4
IIIB	4
IVA + IVB	7
CLIP score	
0	8
1	13
2	7
3	2
4	1
Child–Pugh classification	
A	27
B	4
C	0

ECOG = Eastern Cooperative Oncology Group.

in various types of malignancy, including non–small cell lung cancer, esophageal cancer, head and neck cancer, colon cancer, and lymphoma (9). For diagnosis of HCC, the sensitivity of ^{18}F -FDG PET is only 50%–55% (10–12), yet a recent meta-analysis concluded that ^{18}F -FDG PET is powerful at ruling in extrahepatic metastases and ruling out recurrent HCC (13). Also, some reports have suggested that ^{18}F -FDG PET is a potent predictor of treatment outcome in patients with HCC after hepatectomy, liver transplantation, radiofrequency ablation, and transarterial chemoembolization (14–21). However, there is only a single report on ^{18}F -FDG PET as a predictor of 1-mo response after radiation therapy. Kim et al. found that higher ^{18}F -FDG uptake resulted in better response in patients with HCC 1 mo after completion of conventionally fractionated radiation therapy (22). Still, no study has focused on the association of ^{18}F -FDG PET and tumor control after SABR. Moreover, the role of ^{18}F -FDG PET in the actual tumor control rate during long-term follow-up remains unclear.

The aim of this study was to examine our hypothesis that ^{18}F -FDG PET is a useful tool to predict tumor control for patients with HCC treated by SABR. We also sought to evaluate the prognostic values among various ^{18}F -FDG PET parameters and determine the independent predictors.

MATERIALS AND METHODS**Patients**

From November 2007 to September 2011, 171 patients with HCC were treated at the Cyberknife Stereotactic Radiosurgery Center, Tri-Service General Hospital, Taipei, Taiwan. Among them, 31 patients with 41 lesions underwent ^{18}F -FDG PET before SABR. Data were collected from the cancer registry of Tri-Service General Hospital. Diagnosis was by cytohistology or noninvasive criteria. The diagnosis was made if there was a nodule larger than 2 cm together with the classic enhancement on 1 imaging technique or an α -feto protein (AFP) level higher than 200 ng/mL. The diagnosis was also made if there was a 1- to 2-cm nodule with typical features on 2 imaging studies (23). Before SABR, the medical history of the patients was taken, and they underwent physical examination; testing of complete blood count, serum biochemistry, and AFP; chest radiography; and MR imaging or CT of the abdomen. Liver angiography and bone scanning were optional for some patients if clinically indicated.

All patients were retrospectively restaged according to the American Joint Committee on Cancer (AJCC) staging manual, seventh edition. Written informed consent was obtained from all patients before

TABLE 2
Tumor Characteristics

Characteristic	Value
Number of patients	31
Number of lesions	41
Tumor volume on CT (cm^3)	
Median	51.0
Mean \pm SD	120.9 \pm 222.4
Range	1.6–1,202.7
Tumor size on CT (cm)	
Mean \pm SD	4.5 \pm 2.5
Range	1.5–10.8
Visual ^{18}F -FDG uptake	
Negative	23
Positive	18
T_{SUVmax}	
Median	3.5
Mean \pm SD	3.8 \pm 1.4
Range	1.9–8.4
T_{SUVmean}	
Median	2.9
Mean \pm SD	3.0 \pm 0.9
Range	1.7–5.6
$T_{\text{SUVmax}}/L_{\text{SUVmax}}$	
Median	1.15
Mean \pm SD	1.4 \pm 0.6
Range	0.4–3.2
$T_{\text{SUVmax}}/L_{\text{SUVmean}}$	
Median	1.36
Mean \pm SD	1.6 \pm 0.7
Range	0.5–3.8
CT/ ^{18}F -FDG PET score	
≤ 4	16
> 4	25
SABR dose (Gy)	
Median	42
Mean \pm SD	41.4 \pm 6
Range	30–50
SABR dose per fraction (Gy)	
Median	9
Range	6–12

therapy, and the study was approved by the institutional review board of Tri-Service General Hospital. The detailed patient and tumor characteristics are listed in Tables 1 and 2, respectively.

SABR

Details of our SABR protocol, target delineation, treatment planning techniques, planning evaluation, and constraints of dose-limiting organs have been previously published (6). In short, SABR was delivered with the Cyberknife (Accuray Inc.) image-guided radiosurgery system. Treatment-planning CT images were obtained at 1 mm per slice 1 wk after fiducial placement. Target delineation was based on the visible tumor volume on contrast-enhanced imaging. Treatment planning was conducted with Multiplan Cyberknife planning software, and a Synchrony respiratory tracking system (Accuray Inc.) was used for real-time tumor tracking. The median prescribed dose was 42 Gy (range, 30–50 Gy) in 4–5 fractions on 4–5 consecutive working days. The normal liver dose constraint was set at more than 700 cm³ of normal liver receiving less than 15 Gy.

¹⁸F-FDG PET and Associated Parameters

¹⁸F-FDG PET was performed before SABR using an integrated PET/CT scanner (Biograph BGO duo; Siemens Medical Solutions). The patients fasted for more than 6 h, and their blood glucose levels were less than 150 mg/dL before the injection of 370 MBq of ¹⁸F-FDG tracer. Acquisition of the PET images began 1 h after the injection.

Quantitative analysis of ¹⁸F-FDG uptake was performed to obtain ¹⁸F-FDG PET parameters. The standardized uptake value (SUV) was calculated as follows:

$$\text{SUV} = \frac{C \text{ (kBq/mL)}}{\text{ID (kBq)/body weight (g)}}$$

Where C was tissue activity concentration measured by PET and ID was injected dose. The maximal SUV of the tumor (T_{SUVmax}) was defined as the highest SUV in the tumor. T_{SUVmean} represented the mean SUV of the tumor. To evaluate the SUV of the normal liver, 2 regions of interest containing about 100 pixels were circled on normal

liver of the right lobe, with at least a 5-cm separation. Another region of interest containing about 100 pixels was drawn on normal liver of the left lobe. The maximal SUV of normal liver (L_{SUVmax}) was defined as the highest SUV among the 3 regions of interest. The mean SUV of normal liver (L_{SUVmean}) was the average of the mean of the 3 regions of interest in normal liver. As a result, we obtained PET parameters of visual PET scale (+/–), T_{SUVmax} , $T_{\text{SUVmax}}/L_{\text{SUVmax}}$, and $T_{\text{SUVmax}}/L_{\text{SUVmean}}$.

T_{SUVmax} indicates the highest ¹⁸F-FDG uptake in tumor cells but does not represent tumor burden. Therefore, we created a new scoring system, CT/¹⁸F-FDG PET score, by combining T_{SUVmax} on ¹⁸F-FDG PET and tumor volume on contrast CT. First, we arbitrarily divided tumors into 4 groups by the quartile of T_{SUVmax} , and then we scored them as 1–4 points (≤ 2.8 , 1 point; 2.9–3.4, 2 points; 3.5–4.2, 3 points; > 4.2 , 4 points). Second, we arbitrarily categorized tumors into 4 groups by the quartile of tumor volume (0–10 cm³, 1 point; 10–50 cm³, 2 points; 50–125 cm³, 3 points; > 125 cm³, 4 points). The CT/¹⁸F-FDG PET score of each tumor was the sum of these 2 scores. All tumors were further divided into a high-CT/¹⁸F-FDG PET score group (> 4) and a low-CT/¹⁸F-FDG PET score group (≤ 4).

Follow-up and Assessment

All patients were followed every 1–2 mo for the first 6 mo and every 3 mo thereafter. History taking, physical examinations, complete blood count, prothrombin time/activated partial thromboplastin time, serum biochemistry, and AFP were performed during follow-up. Patients underwent CT scanning or MR imaging 2–3 mo after completion of SABR and then every 3–4 mo. Tumor control was defined as no recurrence within the planning target volume, demonstrated by no new contrast enhancement or progressive disease as defined by the Response Evaluation Criteria in Solid Tumors.

Statistical Analysis

Associations between clinical tumor factors and ¹⁸F-FDG PET parameters were examined by χ^2 testing. We used the Kaplan–Meier method to calculate the tumor control curves (41 tumors) and overall survival curves (31 patients), and the differences between groups

TABLE 3
Associations Between Clinical Tumor Factors and ¹⁸F-FDG PET Parameters

Tumor factor	Visual PET		P	T_{SUVmax}		P	$T_{\text{SUVmax}}/L_{\text{SUVmax}}$		P
	+	–		> 3.2 (n = 26)	≤ 3.2 (n = 15)		> 1.15 (n = 21)	≤ 1.15 (n = 20)	
Viral hepatitis			0.987			0.575			0.606
Non-hepatitis B virus	7	9		11	5		9	7	
Hepatitis B virus	11	14		15	10		12	13	
AJCC stage			0.678			0.536			0.155
I/II	9	13		13	9		9	13	
III/IV	9	10		13	6		12	7	
CLIP score			0.121			0.221			0.116
≤ 1	10	18		16	12		12	16	
> 1	8	5		10	3		9	4	
Child–Pugh classification			0.796			0.613			0.959
A	16	21		23	14		19	18	
B	2	2		3	1		2	2	
AFP			0.001			0.147			0.062
≤ 100	7	20		15	12		11	16	
> 100	11	3		11	3		10	4	
Tumor volume (cm ³)			0.035			0.008			0.019
≤ 40	5	14		8	11		6	13	
> 40	13	9		18	4		15	7	

TABLE 4
Prognostic Factors on Tumor Control After SABR by Cox Proportional Hazards Model

Variable	Crude hazard ratio	P	Adjusted hazard ratio*	P
Age, ≥ 60 vs. < 60 y	1.23 (0.38–3.95)	0.729		
Sex, female vs. male	0.38 (0.05–2.93)	0.354		
ECOG, 1/2 vs. 0	0.99 (0.33–2.98)	0.985		
AJCC stage, III/IV vs. I/II	2.09 (0.72–6.05)	0.176		
CLIP score, > 1 vs. ≤ 1	1.87 (0.62–5.65)	0.266		
Child–Pugh B vs. A	0.04 (0.01–471.94)	0.509		
AFP, > 100 vs. ≤ 100 ng/mL	1.05 (0.33–3.34)	0.941		
SABR dose, > 40 vs. ≤ 40 Gy	0.96 (0.33–2.78)	0.942		
Tumor volume, > 40 vs. ≤ 40 cm ³	2.65 (0.83–8.47)	0.100	1.79 (0.44–7.39) [†]	0.419
Visual ¹⁸ F-FDG uptake, + vs. –	2.24 (0.77–6.47)	0.138	1.95 (0.50–7.52)	0.334
T _{SUVmax} , > 3.2 vs. ≤ 3.2	4.99 (1.10–22.51)	0.037	9.40 (1.18–74.76)	0.034
T _{SUVmean} , > 2.9 vs. ≤ 2.9	1.38 (0.48–3.98)	0.552	1.31 (0.42–4.06)	0.644
T _{SUVmax} /L _{SUVmax} , > 1.15 vs. ≤ 1.15	2.23 (0.74–6.71)	0.152	1.61 (0.45–5.71)	0.461
T _{SUVmax} /L _{SUVmean} , > 1.25 vs. ≤ 1.25	2.43 (0.68–8.75)	0.173	1.31 (0.28–6.07)	0.734
CT/ ¹⁸ F-FDG PET score, > 4 vs. ≤ 4	5.23 (1.17–23.47)	0.031	4.96 (1.05–23.40) [†]	0.043

*Adjusted for sex, AJCC stage, CLIP score, Child–Pugh classification, and tumor volume.

[†]Adjusted for sex, AJCC stage, CLIP score, and Child–Pugh classification.

ECOG = Eastern Cooperative Oncology Group.

Data in parentheses are 95% confidence intervals.

were assessed using the log-rank test. The Cox proportional hazards regression model was used to estimate relative risk of tumor failure. We also determined the adjusted hazard ratio and confidence interval for tumor failure after adjusting factors of sex, AJCC stage, Cancer of the Liver Italian Program (CLIP) score, Child–Pugh classification, and tumor volume. All tests were 2-sided, and a *P* value of less than 0.05 was considered statistically significant. Data were analyzed using SPSS (SPSS Inc.), version 17.

RESULTS

Clinical Tumor Factors and ¹⁸F-FDG PET Parameters

Table 1 shows patient characteristics. Men composed 81% of the study population. The mean age of all 31 patients was 63.8 y. Most were carriers of hepatitis B, with Child–Pugh A liver function. Their performance status was generally good. Table 2 demonstrates tumor characteristics, including CT parameters, ¹⁸F-FDG PET parameters, and radiation dose prescribed. The mean tumor size was 4.5 cm, and mean tumor volume was 120.9 mL. The median value of T_{SUVmax}, T_{SUVmean}, T_{SUVmax}/L_{SUVmax}, and T_{SUVmax}/L_{SUVmean} was 3.5, 2.9, 1.15, and 1.36, respectively. The median prescribed dose was 42 Gy, ranging from 30 to 50 Gy.

Table 3 shows the associations between clinical tumor factors and ¹⁸F-FDG PET parameters. Tumor volume (> 40 vs. ≤ 40 cm³) and AFP level (> 100 vs. ≤ 100 ng/mL) correlated statistically with ¹⁸F-FDG PET parameters. Forty-four percent of tumors showed positive ¹⁸F-FDG uptake by visual interpretation. Of them, 11 of 18 patients (61.1%) had a pretreatment AFP level of more than 100 ng/mL, whereas only 3 of 23 patients (13.0%) without visual ¹⁸F-FDG uptake had a pretreatment AFP level of more than 100 ng/mL (*P* = 0.001). In the analysis of associations between tumor volume (> 40 vs. ≤ 40 mL) and visual PET (positive vs. negative), T_{SUVmax} (> 3.2 vs. ≤ 3.2), and T_{SUVmax}/L_{SUVmax} level (> 1.15 vs. ≤ 1.15), all showed significant correlations.




FIGURE 1. Tumor control curves separated by visual PET (+ vs. –) (A), T_{SUVmax} (> 3.2 vs. ≤ 3.2) (B), T_{SUVmax}/L_{SUVmax} (> 1.15 vs. ≤ 1.15) (C), and CT/¹⁸F-FDG PET score (> 4 vs. ≤ 4) (D).




FIGURE 2. Overall survival curves separated by visual PET (+ vs. -) (A), T_{SUVmax} (>3.2 vs. ≤ 3.2) (B), T_{SUVmax}/L_{SUVmax} (>1.15 vs. ≤ 1.15) (C), and CT/ ^{18}F -FDG PET score (>4 vs. ≤ 4) (D).

Tumor Control and ^{18}F -FDG PET Parameters

The median follow-up time was 18 mo. At the time of analysis, 11 of 41 tumors (27%) had recurrence. The 1-, 2-, 3-, and 4-y tumor control rates were 67.0%, 63.3%, 58.4%, and 58.4%, respectively. Table 4 shows the results of the analysis of possible prognostic factors for tumor control after SABR. T_{SUVmax} (>3.2 vs. ≤ 3.2) and CT/ ^{18}F -FDG PET score (>4 vs. ≤ 4) correlated significantly with tumor control. The 4-y control rate was 86.2% in tumors with an T_{SUVmax} of 3.2 or less but was only 37.5% in those with an T_{SUVmax} of greater than 3.2, resulting in a nearly 5-fold increased risk of subsequent local tumor failure in the latter compared with the former. After adjusting factors of sex, AJCC stage, CLIP score, Child-Pugh classification, and tumor volume, tumors with an T_{SUVmax} greater than 3.2 further show a higher risk of tumor failure, with an adjusted hazard ratio of 9.40. CT/ ^{18}F -FDG PET score (≤ 4 vs. >4) was also a significant predictor of

tumor control after SABR. Tumors with a CT/ ^{18}F -FDG PET score of more than 4 had a 5.23-fold risk of tumor failure. After adjustment for factors of sex, AJCC stage, CLIP score, and Child-Pugh classification, these tumors had a 4.96-fold risk of failure after SABR, compared with those having a score of 4 or less.

Figure 1 shows tumor control curves with stratification of visual PET (positive vs. negative), T_{SUVmax} (>3.2 vs. ≤ 3.2), T_{SUVmax}/L_{SUVmax} (>1.15 vs. ≤ 1.15), and CT/ ^{18}F -FDG PET score (>4 vs. ≤ 4). Of them, T_{SUVmax} and CT/ ^{18}F -FDG PET score were independent indicators for tumor control.

Overall Survival and ^{18}F -FDG PET Parameters

Among 31 patients, 9 patients died and 22 were alive at the time of analysis, resulting in 1-, 2-, 3-, and 4-y overall survival rates of 85.3%, 67.1%, 57.5%, and 57.5%, respectively. Figure 2 shows the overall survival curves of different groups according to different variables and stratifications. Patients with lower T_{SUVmax} , lower T_{SUVmax}/L_{SUVmax} , lower CT/ ^{18}F -FDG PET score, and negative visual PET had a trend toward a higher overall survival rate, but

none was statistically significant. Patients with a T_{SUVmax} level of 3.2 or less had 1-, 2-, and 4-y overall survival rates of 100%, 83.3%, and 83.3%, respectively, whereas the respective rates in those with a T_{SUVmax} level of more than 3.2 were 78.9%, 58.5%, and 43.9%. All patients with a CT/ ^{18}F -FDG PET score of 4 or less were alive at the last follow-up, whereas only 45.5% of patients with a CT/ ^{18}F -FDG PET score of more than 4 were alive. Examples of 2 representative cases are shown in Figures 3 and 4.

DISCUSSION

HCC is one of the major public health problems, with an increased incidence globally. It is biologically and clinically heterogeneous, demanding identification of variables that are helpful in predicting disease behavior before therapy. To the best of our knowledge, this was the first study to investigate whether ^{18}F -FDG PET is useful as a prognostic indicator for HCC patients treated with SABR. We find that it seems to be a significant predictor for local tumor control. Tumors with a T_{SUVmax} of 3.2 or less were well controlled by SABR, with a 4-y control rate of 86.2%, whereas the rate was only 37.5% in those with a T_{SUVmax} of more than 3.2. This finding supports our hypothesis that ^{18}F -FDG PET may be a powerful tool to predict tumor control of HCC.

Previous studies of ^{18}F -FDG PET as a prognostic indicator for HCC focused largely on patients who underwent liver transplantation, resection, radiofrequency ablation, and transarterial chemoembolization




FIGURE 3. Pretreatment enhanced CT scan (A), PET scan (B), and 7 mo posttreatment enhanced CT scan (C) of tumor (arrow) that was positive on visual PET and had a T_{SUVmax} of 4.3, T_{SUVmax}/L_{SUVmax} of 1.23, and CT/ ^{18}F -FDG PET score of 6. Patient underwent SABR of 45 Gy in 5 fractions. Tumor recurred at 7 mo after SABR.




FIGURE 4. Pretreatment enhanced CT scan (A), PET scan (B), and 18 mo posttreatment enhanced CT scan (C) of patient with moderately differentiated HCC (arrow). Visual PET, T_{SUVmax} , T_{SUVmax}/L_{SUVmax} , and CT/ ^{18}F -FDG PET score were negative, 2.5, 1.04, and 4, respectively. Patient underwent SABR of 33 Gy in 5 fractions. Tumor was well controlled during follow-up.

(14–21). Most of these studies showed that lower ^{18}F -FDG uptake was associated with a better outcome. Lee et al. reported that T_{SUVmax}/L_{SUVmax} level was the most significant variable. Patients with a T_{SUVmax}/L_{SUVmax} level of less than 1.15 had a much higher 1-y recurrence-free survival rate (97% vs. 57%, $P < 0.001$) (20). Kornberg et al. showed that visual PET (–) was the best pretransplant prognostic factor for recurrence-free survival. Its prognostic power was even stronger than that of the Milan criteria (18). Hatano et al. studied 31 HCC patients who underwent preoperative ^{18}F -FDG PET and concluded that a lower SUV ratio (<2) is significantly associated with longer overall survival after liver resection (5-y overall survival: 63% vs. 29%, $P = 0.006$) (16).

Kim et al. presented the only publication evaluating the prognostic value of ^{18}F -FDG PET in HCC patients who underwent radiation therapy (22). They retrospectively analyzed 35 HCC patients who were treated with conventionally fractionated radiation therapy with a median total dose of 45 Gy in a daily dose of 1.8–2 Gy. Initial response was determined using the Response Evaluation Criteria in Solid Tumors 1 mo after completion of radiation therapy. A higher SUV ratio (tumor-to-nontumor ratio of SUV) (≥ 2.5) resulted in a better 1-mo objective response rate (80% vs. 40%, $P = 0.015$). However, it is still unknown whether a lower SUV ratio can result in long-term tumor control—a more important endpoint than early response rate when we examine the application of SABR in HCC patients.

^{18}F -FDG uptake denotes the degree of glucose metabolism, which often refers to the aggressiveness of the cancer cells. In this study, we used the CT/ ^{18}F -FDG PET score to include T_{SUVmax} and tumor volume on contrast-enhanced CT. This score appears to be an independent prognostic indicator, with an adjusted hazard ratio of 4.96. However, it does not further enhance the predictive power in comparison with T_{SUVmax} alone. As a result, we found that, among all ^{18}F -FDG PET parameters we analyzed, T_{SUVmax} with a cutoff value of 3.2 was the best indicator of tumor control after SABR.

Accordingly, ^{18}F -FDG PET has great potential for optimizing patient selection and may reduce the side effects and costs of ineffective SABR. For patients with a T_{SUVmax} of more than 3.2, other locoregional or systemic therapies may be considered first. Alternatively, a combination of SABR and other treatment modalities, such as transarterial chemoembolization, alcohol injection, sorafenib, and thalidomide, may be tested in future clinical trials.

T_{SUVmax} can serve as a reference for radiation dose prescription. One of those major unsolved problems regarding the application

of SABR in HCC is how much radiation should be delivered to optimize tumor control while limiting toxicity. This study showed that the dose we prescribed (median, 42 Gy; range, 30–50 Gy) resulted in good local control for tumors with a T_{SUVmax} of 3.2 or less. However, those with a T_{SUVmax} of more than 3.2 demonstrated radioresistance at the dose we prescribed. This finding may imply that dose escalation for tumors with a T_{SUVmax} of more than 3.2 is needed to improve tumor killing and will lead to better results.

The major limitation of the present study was that it was a retrospective single-institution study with a small sample size, caused by the fact that PET is not a routine

study for HCC to date. Although the use of SABR for HCC has been gaining popularity recently, worldwide only a few institutes perform this novel radiation therapy technique, and the total treatment number is still small.

CONCLUSION

The findings of this study support the use of ^{18}F -FDG PET to predict tumor control for patients with HCC treated by SABR. Among all the ^{18}F -FDG PET parameters we surveyed, T_{SUVmax} with a cutoff value of 3.2 was the best prognostic indicator. SABR for HCC with a T_{SUVmax} of 3.2 or less resulted in a 4-y tumor control rate of 86.2%, whereas the rate was only 37.5% in those with a T_{SUVmax} of more than 3.2. We suggest that the use of ^{18}F -FDG PET may be applicable for patient selection, prognostic prediction, and radiation dose adjustment. A large-scale multicenter clinical trial to evaluate the prognostic role of ^{18}F -FDG PET in HCC patients treated with SABR may be justifiable.

DISCLOSURE

The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734. The study was supported in part by the study projects of TSGH C101-056 and TSGH-C102-055. No other potential conflict of interest relevant to this article was reported.

ACKNOWLEDGMENT

We thank the Cancer Registry of Tri-Service General Hospital for helping with data collection.

REFERENCES

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer*. 2010;127:2893–2917.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin*. 2011;61:69–90.
3. El-Serag HB. Hepatocellular carcinoma. *N Engl J Med*. 2011;365:1118–1127.
4. Choi BO, Choi IB, Jang HS, et al. Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis. *BMC Cancer*. 2008;8:351.
5. Choi BO, Jang HS, Kang KM, et al. Fractionated stereotactic radiotherapy in patients with primary hepatocellular carcinoma. *Jpn J Clin Oncol*. 2006;36:154–158.

6. Huang WY, Jen YM, Lee MS, et al. Stereotactic body radiation therapy in recurrent hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys.* 2012;84:355–361.
7. Louis C, Dewas S, Mirabel X, et al. Stereotactic radiotherapy of hepatocellular carcinoma: preliminary results. *Technol Cancer Res Treat.* 2010;9:479–487.
8. Tse RV, Hawkins M, Lockwood G, et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. *J Clin Oncol.* 2008;26:657–664.
9. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. *N Engl J Med.* 2006;354:496–507.
10. Jeng LB, Changlai SP, Shen YY, Lin CC, Tsai CH, Kao CH. Limited value of ¹⁸F-2-deoxyglucose positron emission tomography to detect hepatocellular carcinoma in hepatitis B virus carriers. *Hepatogastroenterology.* 2003;50:2154–2156.
11. Khan MA, Combs CS, Brunt EM, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. *J Hepatol.* 2000;32:792–797.
12. Trojan J, Schroeder O, Raedle J, et al. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. *Am J Gastroenterol.* 1999;94:3314–3319.
13. Lin CY, Chen JH, Liang JA, Lin CC, Jeng LB, Kao CH. ¹⁸F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma: a systematic review and meta-analysis. *Eur J Radiol.* 2012;81:2417–2422.
14. Anderson GS, Brinkmann F, Soulen MC, Alavi A, Zhuang H. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. *Clin Nucl Med.* 2003;28:192–197.
15. Cascales Campos P, Ramirez P, Gonzalez R, et al. Value of 18-FDG-positron emission tomography/computed tomography before and after transarterial chemoembolization in patients with hepatocellular carcinoma undergoing liver transplantation: initial results. *Transplant Proc.* 2011;43:2213–2215.
16. Hatano E, Ikai I, Higashi T, et al. Preoperative positron emission tomography with fluorine-18-fluorodeoxyglucose is predictive of prognosis in patients with hepatocellular carcinoma after resection. *World J Surg.* 2006;30:1736–1741.
17. Higashi T, Hatano E, Ikai I, et al. FDG PET as a prognostic predictor in the early post-therapeutic evaluation for unresectable hepatocellular carcinoma. *Eur J Nucl Med Mol Imaging.* 2010;37:468–482.
18. Kornberg A, Kupper B, Tannapfel A, et al. Patients with non-[¹⁸F]fludeoxyglucose-avid advanced hepatocellular carcinoma on clinical staging may achieve long-term recurrence-free survival after liver transplantation. *Liver Transpl.* 2012;18:53–61.
19. Kornberg A, Kupper B, Thrum K, et al. Increased ¹⁸F-FDG uptake of hepatocellular carcinoma on positron emission tomography independently predicts tumor recurrence in liver transplant patients. *Transplant Proc.* 2009;41:2561–2563.
20. Lee JW, Paeng JC, Kang KW, et al. Prediction of tumor recurrence by ¹⁸F-FDG PET in liver transplantation for hepatocellular carcinoma. *J Nucl Med.* 2009;50:682–687.
21. Yang SH, Suh KS, Lee HW, et al. The role of ¹⁸F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. *Liver Transpl.* 2006;12:1655–1660.
22. Kim JW, Seong J, Yun M, et al. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in predicting treatment response in unresectable hepatocellular carcinoma patients treated with external beam radiotherapy. *Int J Radiat Oncol Biol Phys.* 2012;82:1172–1178.
23. Bruix J, Sherman M. Management of hepatocellular carcinoma. *Hepatology.* 2005;42:1208–1236.



The Journal of
NUCLEAR MEDICINE

^{18}F -FDG PET and Combined ^{18}F -FDG–Contrast CT Parameters as Predictors of Tumor Control for Hepatocellular Carcinoma After Stereotactic Ablative Radiotherapy

Wen-Yen Huang, Chia-Hung Kao, Wen-Sheng Huang, Chang-Ming Chen, Li-Ping Chang, Meei-Shyuan Lee, Hsing-Lung Chao, Chuang-Hsin Chiu, Cheng-Hsiang Lo and Yee-Min Jen

J Nucl Med. 2013;54:1710-1716.

Published online: August 22, 2013.

Doi: 10.2967/jnumed.112.119370

This article and updated information are available at:

<http://jnm.snmjournals.org/content/54/10/1710>

Information about reproducing figures, tables, or other portions of this article can be found online at:

<http://jnm.snmjournals.org/site/misc/permission.xhtml>

Information about subscriptions to JNM can be found at:

<http://jnm.snmjournals.org/site/subscriptions/online.xhtml>

The Journal of Nuclear Medicine is published monthly.
SNMMI | Society of Nuclear Medicine and Molecular Imaging
1850 Samuel Morse Drive, Reston, VA 20190.
(Print ISSN: 0161-5505, Online ISSN: 2159-662X)

© Copyright 2013 SNMMI; all rights reserved.

 SOCIETY OF
NUCLEAR MEDICINE
AND MOLECULAR IMAGING